Vyome Secures Key U.S. Patent for VT-1908, Targeting $20B Ocular Inflammation Market
Event summary
- Vyome received a Notice of Allowance from the USPTO for its VT-1908 patent application, covering formulations and methods for treating inflammatory eye diseases.
- VT-1908 is a novel topical ophthalmic formulation of mycophenolate, initially targeting anterior uveitis.
- The global ocular inflammation market is estimated to exceed $20 billion by 2035.
- Preclinical results published in February 2026 demonstrated VT-1908's efficacy in reducing inflammation in a uveitis model.
The big picture
Vyome's patent milestone for VT-1908 strengthens its intellectual property position in the rapidly growing ocular inflammation market. The company is positioning VT-1908 as a non-steroidal alternative, addressing a significant unmet need for steroid-sparing therapies. This development aligns with broader industry trends toward targeted immuno-inflammatory treatments, potentially disrupting the current steroid-dominated market.
What we're watching
- Market Expansion
- Whether Vyome can successfully expand VT-1908's application beyond anterior uveitis to other ocular inflammatory conditions.
- Regulatory Progress
- The pace at which Vyome advances VT-1908 through clinical trials and secures regulatory approval.
- Competitive Positioning
- How VT-1908's steroid-sparing potential will position it against existing treatments in the $20B ocular inflammation market.